Dossier assessment
Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy, and who are candidates for high-dose therapy
Hint of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2024-12-19 A G-BA decision was published.
Project details
- Project no.
- A24-71
- Commission
- Commission awarded on 01.07.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-71_en
Connected Projects
-
Dossier assessment
Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Addendum
Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71
Status: Commission completed